CA
AQST icon

Clearstead Advisors’s Aquestive Therapeutics AQST Stock Holding History

Clearstead Advisors’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21 Buy
+5
New +$21 ﹤0.01% 3577

Other funds holding AQST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
EAM
Everstar Asset Management Mooresville, North Carolina $207M AUM 18.14% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Clearstead Advisors's AQST Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Aquestive Therapeutics (AQST) in Q2 2026: 5 shares worth $21. The stake represents ﹤0.01% of the portfolio and ranks #3577 among its holdings.

72 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Clearstead Advisors held 5 shares of Aquestive Therapeutics worth $21 as of Q2 2026.
  • Aquestive Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Aquestive Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3577 holding.
  • 72 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.